These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11122270)

  • 21. Inhibitors in patients with haemophilia A.
    Kreuz W; Ettingshausen CE
    Thromb Res; 2014 Nov; 134 Suppl 1():S22-6. PubMed ID: 24745722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR; Tuller J; Johnson JA
    Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitors in haemophilia A: current management and open issues.
    Haya S; Moret A; Cid AR; Cortina V; Casaña P; Cabrera N; Aznar JA
    Haemophilia; 2007 Dec; 13 Suppl 5():52-60. PubMed ID: 18078398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-reactivity to porcine factor VIII of factor VIII inhibitors in patients with haemophilia in Australia and New Zealand.
    Lloyd JV; Street AM; Berry E; McPherson J; Ekert H; Lammi A; McWhirter WR; Duncan EM; Maxwell EL; Rowell J; Baker RI; Leahy MF; Jupe D
    Aust N Z J Med; 1997 Dec; 27(6):658-64. PubMed ID: 9483232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro.
    Astermark J; Voorberg J; Lenk H; DiMichele D; Shapiro A; Tjönnfjord G; Berntorp E
    Haemophilia; 2003 Sep; 9(5):567-72. PubMed ID: 14511295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
    Luna-Záizar H; Beltrán-Miranda CP; Esparza-Flores MA; Soto-Padilla J; Bergés-García A; Rodríguez-Zepeda MD; Pompa-Garza MT; Jaloma-Cruz AR
    Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A.
    Delignat S; Repessé Y; Navarrete AM; Meslier Y; Gupta N; Christophe OD; Kaveri SV; Lacroix-Desmazes S
    Haemophilia; 2012 Mar; 18(2):248-54. PubMed ID: 22044692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
    Federici AB
    Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors.
    Kurth MA; Dimichele D; Sexauer C; Sanders JM; Torres M; Zappa SC; Ragni M; Leonard N
    Haemophilia; 2008 Jan; 14(1):50-5. PubMed ID: 17941829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations.
    Berntorp E; Ekman M; Gunnarsson M; Nilsson IM
    Haemophilia; 1996 Apr; 2(2):95-9. PubMed ID: 27214015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
    Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of VWF for the success of immune tolerance induction.
    Kreuz W
    Thromb Res; 2008; 122 Suppl 2():S7-S12. PubMed ID: 18549910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low factor VIII recovery in haemophilia A patients without inhibitor titre is not due to the presence of anti-factor VIII antibodies undetectable by the Bethesda assay.
    Mondorf W; Klinge J; Luban NL; Bray G; Saenko E; Scandella D;
    Haemophilia; 2001 Jan; 7(1):13-9. PubMed ID: 11136375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
    Yada K; Nogami K; Shima M
    Br J Haematol; 2013 Oct; 163(1):104-11. PubMed ID: 23889549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case-control study.
    van Velzen AS; Eckhardt CL; Peters M; Oldenburg J; Cnossen M; Liesner R; Morfini M; Castaman G; McRae S; van der Bom JG; Fijnvandraat K;
    Br J Haematol; 2020 Jun; 189(6):1182-1191. PubMed ID: 32201943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-reacting recombinant porcine FVIII inhibitors in patients with acquired haemophilia A.
    Bowyer A; Shepherd F; Platton S; Guy S; Kitchen S; Maclean R
    Haemophilia; 2020 Nov; 26(6):1181-1186. PubMed ID: 32997894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New predictive approaches for ITI treatment.
    Minno GD; Santagostino E; Pratt K; Königs C
    Haemophilia; 2014 Sep; 20 Suppl 6():27-43. PubMed ID: 24975702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.